Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

23.56
+0.10000.43%
Post-market: 23.560.00000.00%19:32 EST
Volume:2.36M
Turnover:55.83M
Market Cap:3.99B
PE:15.29
High:24.04
Open:24.04
Low:23.37
Close:23.46
52wk High:28.35
52wk Low:13.40
Shares:169.18M
Float Shares:115.85M
Volume Ratio:1.68
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.54
EPS(LYR):1.37
ROE:34.95%
ROA:5.11%
PB:4.35
PE(LYR):17.24

Loading ...

ACADIA Pharmaceuticals Is Maintained at Perform by Oppenheimer

Dow Jones
·
Yesterday

BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts

Reuters
·
Feb 06

ACADIA Pharmaceuticals Inc. kündigt Veröffentlichung von Finanzzahlen an

Reuters
·
Feb 05

Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Feb 04

ACADIA Pharmaceuticals Price Target Maintained With a $37.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 03

ACADIA Pharmaceuticals Inc. : Deutsche Bank Cuts Target Price to $32 From $33

THOMSON REUTERS
·
Feb 03

U.S. RESEARCH ROUNDUP-Adobe, Exxon Mobil, Stellar Bancorp

Reuters
·
Feb 03

BUZZ-Australia's Neuren sinks on setback for Rett treatment drug application from European regulator

Reuters
·
Feb 03

Acadia Expects Negative Opinion from EU Regulators for Rett Syndrome Treatment

Dow Jones
·
Feb 03

BRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union

Reuters
·
Feb 03

ACADIA Pharmaceuticals Inc - to Request Re-Examination of Chmp Opinion

THOMSON REUTERS
·
Feb 03

ACADIA Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

THOMSON REUTERS
·
Feb 03

ACADIA Pharmaceuticals Inc - Receives Negative Trend Vote on Trofinetide Maa

THOMSON REUTERS
·
Feb 03

U.S. RESEARCH ROUNDUP-Air Products, Chevron, UnitedHealth

Reuters
·
Feb 02

Acadia Pharmaceuticals a solid opportunity here, says Canaccord

TIPRANKS
·
Jan 30

RBC Raises Price Target on ACADIA Pharmaceuticals to $35 From $33, Keeps Outperform Rating

MT Newswires Live
·
Jan 20

Neuren Shares Rise on Higher Daybue Sales Forecast

Dow Jones
·
Jan 14

ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment

TIPRANKS
·
Jan 14

ACADIA Pharmaceuticals Inc - Anticipates 2025 Net Sales to Exceed $1 Bln - SEC Filing

THOMSON REUTERS
·
Jan 14

Acadia Pharmaceuticals projects $1.7 billion in net sales by 2028

Reuters
·
Jan 13